Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

TAp63-regulated microRNAs suppress cutaneous squamous cell carcinoma through inhibition of a network of cell cycle genes.

Davis AJ, Tsinkevich M, Rodencal J, Abbas HA, Su XH, Gi YJ, Fang B, Rajapakshe K, Coarfa C, Gunaratne PH, Koomen JM, Tsai KY, Flores ER.

Cancer Res. 2020 Mar 10. pii: canres.1892.2019. doi: 10.1158/0008-5472.CAN-19-1892. [Epub ahead of print]

PMID:
32156775
2.

DNA hyper-methylation during Tuberculosis dampens host immune responsiveness.

DiNardo A, Rajapakshe K, Nishiguchi T, Mtetwa G, Grimm SL, Dlamini Q, Kahari J, Mahapatra S, Kay AW, Maphalala G, Mace EM, Makedonas G, Cirillo JD, Netea M, van Crevel R, Coarfa C, Mandalakas AM.

J Clin Invest. 2020 Mar 3. pii: 134622. doi: 10.1172/JCI134622. [Epub ahead of print]

3.

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.

Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B, Karki B, Hailemichael Y, Singh M, Vianden C, Vennam S, Bharadwaj U, Tweardy DJ, Haymaker C, Bernatchez C, Huang S, Rajapakshe K, Coarfa C, Hurwitz ME, Sznol M, Hwu P, Hoch U, Addepalli M, Charych DH, Zalevsky J, Diab A, Overwijk WW.

Nat Commun. 2020 Jan 31;11(1):661. doi: 10.1038/s41467-020-14471-1.

4.

A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.

Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C.

Clin Cancer Res. 2020 Mar 1;26(5):990-999. doi: 10.1158/1078-0432.CCR-19-2389. Epub 2020 Jan 15.

PMID:
31941830
5.

Critical Role of Cytosolic DNA and Its Sensing Adaptor STING in Aortic Degeneration, Dissection, and Rupture.

Luo W, Wang Y, Zhang L, Ren P, Zhang C, Li Y, Azares AR, Zhang M, Guo J, Ghaghada KB, Starosolski ZA, Rajapakshe K, Coarfa C, Li Y, Chen R, Fujiwara K, Abe JI, Coselli JS, Milewicz DM, LeMaire SA, Shen YH.

Circulation. 2020 Jan 7;141(1):42-66. doi: 10.1161/CIRCULATIONAHA.119.041460. Epub 2019 Dec 30.

PMID:
31887080
6.

MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin.

Patil SL, Palat A, Pan Y, Rajapakshe K, Mirchandani R, Bondesson M, Yustein JT, Coarfa C, Gunaratne PH.

Sci Rep. 2019 Dec 13;9(1):19089. doi: 10.1038/s41598-019-55170-2.

7.

Correction: Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer.

Vantaku V, Donepudi SR, Ambati CR, Jin F, Putluri V, Nguyen K, Rajapakshe K, Coarfa C, Battula VL, Lotan Y, Putluri N.

Oncotarget. 2019 Nov 26;10(63):6843-6844. doi: 10.18632/oncotarget.27311. eCollection 2019 Nov 26.

8.

Loss of the E2 SUMO-conjugating enzyme Ube2i in oocytes during ovarian folliculogenesis causes infertility in mice.

Rodriguez A, Briley SM, Patton BK, Tripurani SK, Rajapakshe K, Coarfa C, Rajkovic A, Andrieux A, Dejean A, Pangas SA.

Development. 2019 Dec 2;146(23). pii: dev176701. doi: 10.1242/dev.176701.

PMID:
31704792
9.

Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer.

Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, Fiskus W, Rajendran M, Chew SA, Zimmermann M, Bond R, He B, Coarfa C, Mitsiades N.

Cancer Res. 2019 Sep 1;79(17):4552. doi: 10.1158/0008-5472.CAN-19-1981. No abstract available.

10.

Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression.

Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Rajapakshe K, Donepudi SR, von Rundstedt FC, Devarakonda V, Dubrulle J, Karanam B, McGuire SE, Stossi F, Jain AK, Coarfa C, Cao Q, Sikora AG, Villanueva H, Kavuri SM, Lotan Y, Sreekumar A, Putluri N.

Oncogene. 2019 Aug 5. doi: 10.1038/s41388-019-0902-7. [Epub ahead of print]

PMID:
31383940
11.

DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism.

Vantaku V, Amara CS, Piyarathna DWB, Donepudi SR, Ambati CR, Putluri V, Tang W, Rajapakshe K, Estecio MR, Terris MK, Castro PD, Ittmann MM, Williams SB, Lerner SP, Sreekumar A, Bollag R, Coarfa C, Kornberg MD, Lotan Y, Ambs S, Putluri N.

Carcinogenesis. 2019 Nov 25;40(11):1332-1340. doi: 10.1093/carcin/bgz128.

PMID:
31284295
12.

Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland.

Hai L, Szwarc MM, Lonard DM, Rajapakshe K, Perera D, Coarfa C, Ittmann M, Fernandez-Valdivia R, Lydon JP.

Cytokine. 2019 Nov;123:154745. doi: 10.1016/j.cyto.2019.154745. Epub 2019 Jun 18.

PMID:
31226438
13.

Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer.

Bader DA, Hartig SM, Putluri V, Foley C, Hamilton MP, Smith EA, Saha PK, Panigrahi A, Walker C, Zong L, Martini-Stoica H, Chen R, Rajapakshe K, Coarfa C, Sreekumar A, Mitsiades N, Bankson JA, Ittmann MM, O'Malley BW, Putluri N, McGuire SE.

Nat Metab. 2019 Jan;1(1):70-85. doi: 10.1038/s42255-018-0002-y. Epub 2018 Nov 19.

14.

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.

Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN.

Blood. 2019 Jul 4;134(1):59-73. doi: 10.1182/blood.2018893982. Epub 2019 Apr 25.

PMID:
31023702
15.

Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.

Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH.

Cancer. 2019 Jul 15;125(14):2409-2422. doi: 10.1002/cncr.32053. Epub 2019 Apr 23.

16.

A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women.

Jiao L, Maity S, Coarfa C, Rajapakshe K, Chen L, Jin F, Putluri V, Tinker LF, Mo Q, Chen F, Sen S, Sangi-Hyghpeykar H, El-Serag HB, Putluri N.

Cancer Prev Res (Phila). 2019 Apr;12(4):237-246. doi: 10.1158/1940-6207.CAPR-18-0201. Epub 2019 Feb 5.

17.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.

Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN.

Blood Cancer J. 2019 Jan 15;9(2):4. doi: 10.1038/s41408-018-0165-5.

18.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2019 Jun;33(6):1373-1386. doi: 10.1038/s41375-018-0334-3. Epub 2018 Dec 21.

PMID:
30575820
19.

Correction to: The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.

Villanueva H, Grimm SL, Dhamne S, Rajapakshe K, Visbal AP, Davis CM, Ehli EA, Hartig SM, Coarfa C, Edwards DP.

J Mammary Gland Biol Neoplasia. 2019 Mar;24(1):109-110. doi: 10.1007/s10911-018-9421-3.

20.

The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.

Villanueva H, Grimm S, Dhamne S, Rajapakshe K, Visbal A, Davis CM, Ehli EA, Hartig SM, Coarfa C, Edwards DP.

J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):237-248. doi: 10.1007/s10911-018-9416-0. Epub 2018 Oct 18. Review. Erratum in: J Mammary Gland Biol Neoplasia. 2018 Nov 21;:.

21.

TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy.

Jayaraman P, Parikh F, Newton JM, Hanoteau A, Rivas C, Krupar R, Rajapakshe K, Pathak R, Kanthaswamy K, MacLaren C, Huang S, Coarfa C, Spanos C, Edwards DP, Parihar R, Sikora AG.

Oncoimmunology. 2018 Jul 26;7(10):e1490853. doi: 10.1080/2162402X.2018.1490853. eCollection 2018.

22.

Transcriptomic and microRNA analyses of gene networks regulated by eicosapentaenoic acid in brown adipose tissue of diet-induced obese mice.

Pahlavani M, Wijayatunga NN, Kalupahana NS, Ramalingam L, Gunaratne PH, Coarfa C, Rajapakshe K, Kottapalli P, Moustaid-Moussa N.

Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Dec;1863(12):1523-1531. doi: 10.1016/j.bbalip.2018.09.004. Epub 2018 Sep 25.

23.

Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity.

Zhang M, Suarez E, Vasquez JL, Nathanson L, Peterson LE, Rajapakshe K, Basil P, Weigel NL, Coarfa C, Agoulnik IU.

Oncogene. 2019 Feb;38(7):1121-1135. doi: 10.1038/s41388-018-0498-3. Epub 2018 Sep 18.

24.

APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.

Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, South AP.

Sci Transl Med. 2018 Aug 22;10(455). pii: eaas9668. doi: 10.1126/scitranslmed.aas9668.

PMID:
30135250
25.

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Eveline B, Koster J, Perini G, Coarfa C, Shohet JM.

Oncotarget. 2018 Jul 6;9(52):30024. doi: 10.18632/oncotarget.25776. eCollection 2018 Jul 6.

26.

miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity.

Koh EH, Chernis N, Saha PK, Xiao L, Bader DA, Zhu B, Rajapakshe K, Hamilton MP, Liu X, Perera D, Chen X, York B, Trauner M, Coarfa C, Bajaj M, Moore DD, Deng T, McGuire SE, Hartig SM.

Diabetes. 2018 Dec;67(12):2541-2553. doi: 10.2337/db17-1378. Epub 2018 Jul 12.

27.

Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.

Morriss GR, Rajapakshe K, Huang S, Coarfa C, Cooper TA.

Hum Mol Genet. 2018 Aug 15;27(16):2789-2804. doi: 10.1093/hmg/ddy192.

28.

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barbieri E, Koster J, Perini G, Coarfa C, Shohet JM.

Oncotarget. 2018 Apr 17;9(29):20323-20338. doi: 10.18632/oncotarget.24859. eCollection 2018 Apr 17. Erratum in: Oncotarget. 2018 Jul 6;9(52):30024. Eveline, Barberi [corrected to Eveline, Barbieri].

29.

Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes.

DiNardo AR, Nishiguchi T, Mace EM, Rajapakshe K, Mtetwa G, Kay A, Maphalala G, Secor WE, Mejia R, Orange JS, Coarfa C, Bhalla KN, Graviss EA, Mandalakas AM, Makedonas G.

J Immunol. 2018 Jul 1;201(1):124-133. doi: 10.4049/jimmunol.1800101. Epub 2018 May 11.

30.

Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.

Dasgupta S, Rajapakshe K, Zhu B, Nikolai BC, Yi P, Putluri N, Choi JM, Jung SY, Coarfa C, Westbrook TF, Zhang XH, Foulds CE, Tsai SY, Tsai MJ, O'Malley BW.

Nature. 2018 Apr;556(7700):249-254. doi: 10.1038/s41586-018-0018-1. Epub 2018 Apr 3.

31.

GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling.

White MA, Tsouko E, Lin C, Rajapakshe K, Spencer JM, Wilkenfeld SR, Vakili SS, Pulliam TL, Awad D, Nikolos F, Katreddy RR, Kaipparettu BA, Sreekumar A, Zhang X, Cheung E, Coarfa C, Frigo DE.

Endocr Relat Cancer. 2018 Apr;25(4):453-469. doi: 10.1530/ERC-17-0051. Epub 2018 Feb 5.

32.

ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells.

Kaochar S, Dong J, Torres M, Rajapakshe K, Nikolos F, Davis CM, Ehli EA, Coarfa C, Mitsiades N, Poulaki V.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):132-143. doi: 10.1167/iovs.17-22454.

33.

Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer.

Vantaku V, Donepudi SR, Ambati CR, Jin F, Putluri V, Nguyen K, Rajapakshe K, Coarfa C, Battula VL, Lotan Y, Putluri N.

Oncotarget. 2017 Sep 16;8(56):95620-95631. doi: 10.18632/oncotarget.21038. eCollection 2017 Nov 10. Erratum in: Oncotarget. 2019 Nov 26;10(63):6843-6844.

34.

EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma.

Sun W, Rojas Y, Wang H, Yu Y, Wang Y, Chen Z, Rajapakshe K, Xu X, Huang W, Agarwal S, Patel RH, Woodfield S, Zhao Y, Jin J, Zhang H, Major A, Hicks MJ, Shohet JM, Vasudevan SA, Coarfa C, Yang J, Nuchtern JG.

Oncotarget. 2017 Oct 19;8(55):94780-94792. doi: 10.18632/oncotarget.21933. eCollection 2017 Nov 7.

35.

Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes.

Abbas HA, Bui NHB, Rajapakshe K, Wong J, Gunaratne P, Tsai KY, Coarfa C, Flores ER.

Cancer Res. 2018 Jan 15;78(2):451-462. doi: 10.1158/0008-5472.CAN-17-1803. Epub 2017 Nov 27.

36.

A new mild hyperthermia device to treat vascular involvement in cancer surgery.

Ware MJ, Nguyen LP, Law JJ, Krzykawska-Serda M, Taylor KM, Cao HST, Anderson AO, Pulikkathara M, Newton JM, Ho JC, Hwang R, Rajapakshe K, Coarfa C, Huang S, Edwards D, Curley SA, Corr SJ.

Sci Rep. 2017 Sep 12;7(1):11299. doi: 10.1038/s41598-017-10508-6.

37.

Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.

Jin F, Thaiparambil J, Donepudi SR, Vantaku V, Piyarathna DWB, Maity S, Krishnapuram R, Putluri V, Gu F, Purwaha P, Bhowmik SK, Ambati CR, von Rundstedt FC, Roghmann F, Berg S, Noldus J, Rajapakshe K, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Kaipparettu BA, Karanam B, Terris MK, Kavuri SM, Lerner SP, Kheradmand F, Coarfa C, Sreekumar A, Lotan Y, El-Zein R, Putluri N.

Cancer Prev Res (Phila). 2017 Oct;10(10):588-597. doi: 10.1158/1940-6207.CAPR-17-0198. Epub 2017 Aug 29.

38.

miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.

Satterfield L, Shuck R, Kurenbekova L, Allen-Rhoades W, Edwards D, Huang S, Rajapakshe K, Coarfa C, Donehower LA, Yustein JT.

Int J Cancer. 2017 Nov 15;141(10):2062-2075. doi: 10.1002/ijc.30909. Epub 2017 Aug 8.

39.

BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.

Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN.

Leukemia. 2018 Feb;32(2):343-352. doi: 10.1038/leu.2017.207. Epub 2017 Jun 30.

PMID:
28663582
40.

Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.

White MA, Lin C, Rajapakshe K, Dong J, Shi Y, Tsouko E, Mukhopadhyay R, Jasso D, Dawood W, Coarfa C, Frigo DE.

Mol Cancer Res. 2017 Aug;15(8):1017-1028. doi: 10.1158/1541-7786.MCR-16-0480. Epub 2017 May 15.

41.

SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.

Geng C, Kaochar S, Li M, Rajapakshe K, Fiskus W, Dong J, Foley C, Dong B, Zhang L, Kwon OJ, Shah SS, Bolaki M, Xin L, Ittmann M, O'Malley BW, Coarfa C, Mitsiades N.

Oncogene. 2017 Aug 17;36(33):4767-4777. doi: 10.1038/onc.2017.80. Epub 2017 Apr 17.

42.

Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer.

Bhardwaj A, Singh H, Rajapakshe K, Tachibana K, Ganesan N, Pan Y, Gunaratne PH, Coarfa C, Bedrosian I.

Oncotarget. 2017 Mar 21;8(12):19645-19660. doi: 10.18632/oncotarget.14902.

43.

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.

Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2017 Sep;31(9):1951-1961. doi: 10.1038/leu.2016.393. Epub 2017 Feb 2.

44.

Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression.

Blessing AM, Rajapakshe K, Reddy Bollu L, Shi Y, White MA, Pham AH, Lin C, Jonsson P, Cortes CJ, Cheung E, La Spada AR, Bast RC Jr, Merchant FA, Coarfa C, Frigo DE.

Autophagy. 2017 Mar 4;13(3):506-521. doi: 10.1080/15548627.2016.1268300. Epub 2016 Dec 15.

45.

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN.

Leukemia. 2017 Mar;31(3):678-687. doi: 10.1038/leu.2016.260. Epub 2016 Sep 28.

46.

Generation of an in vitro 3D PDAC stroma rich spheroid model.

Ware MJ, Keshishian V, Law JJ, Ho JC, Favela CA, Rees P, Smith B, Mohammad S, Hwang RF, Rajapakshe K, Coarfa C, Huang S, Edwards DP, Corr SJ, Godin B, Curley SA.

Biomaterials. 2016 Nov;108:129-42. doi: 10.1016/j.biomaterials.2016.08.041. Epub 2016 Sep 2.

47.

Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates.

Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY.

Nat Commun. 2016 Aug 30;7:12601. doi: 10.1038/ncomms12601.

48.

Genetic and Environmental Models of Circadian Disruption Link SRC-2 Function to Hepatic Pathology.

Fleet T, Stashi E, Zhu B, Rajapakshe K, Marcelo KL, Kettner NM, Gorman BK, Coarfa C, Fu L, O'Malley BW, York B.

J Biol Rhythms. 2016 Oct;31(5):443-60. doi: 10.1177/0748730416657921. Epub 2016 Jul 17.

49.

The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP.

Hamilton MP, Rajapakshe KI, Bader DA, Cerne JZ, Smith EA, Coarfa C, Hartig SM, McGuire SE.

Neoplasia. 2016 Jun;18(6):356-70. doi: 10.1016/j.neo.2016.04.008.

50.

Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.

Lopez SM, Agoulnik AI, Zhang M, Peterson LE, Suarez E, Gandarillas GA, Frolov A, Li R, Rajapakshe K, Coarfa C, Ittmann MM, Weigel NL, Agoulnik IU.

Clin Cancer Res. 2016 Aug 1;22(15):3937-49. doi: 10.1158/1078-0432.CCR-15-1983. Epub 2016 Mar 11.

Supplemental Content

Loading ...
Support Center